Benzinga | Nov 30, 2020 08:06AM EST

Profound Medical Receives FDA HDE Approval For Sonalleve

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") announced today that Sonalleve(r) has received U.S. Food and Drug Administration ("FDA") approval under a Humanitarian Device Exemption ("HDE") for the treatment of osteoid osteoma.